The biotechnology industry in the US involves companies that use biological systems and organisms to create products and technologies aimed at healthcare and agriculture. These firms focus on developing drugs, therapies, and diagnostics to address health challenges and improve patient outcomes. The sector is evolving rapidly, propelled by advances in genetics, synthetic biology, and precision medicine. A trend towards personalized therapies and increased collaboration among stakeholders marks its future, alongside a surge in investment aimed at innovative treatments, such as gene therapies and biologics that reshape how diseases are treated.

This list showcases 22 prominent biotechnology companies across the US, varying in size from small firms to large corporations. They are headquartered in innovation hubs like California, Massachusetts, and North Carolina, and were founded between 1978 and 2020. Each company specializes in areas such as gene therapy, cancer treatment, protein therapeutics, and biomanufacturing, indicating a broad scope of expertise in the biotech field. Their unique solutions address pressing health issues, demonstrating the significant contributions of this industry's growth.

Read on to discover more about the top biotechnology companies in the US.

Top 20 Biotechnology Companies in the US

1. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to the development of gene therapy treatments for genetic diseases. The company has a clear focus on conditions such as hemophilia and inherited retinal diseases, aiming to create innovative therapies that can transform patient care. Spark Therapeutics operates a fully integrated model that includes research, development, and manufacturing of gene therapies. Their proprietary adeno-associated viral (AAV) gene therapy platform is central to their operations, allowing them to tailor treatments to specific genetic disorders. The company has made significant strides in the industry, highlighted by their flagship product, Luxturna, which was the first approved gene therapy for a genetic disease in both the US and EU. Spark Therapeutics is also a member of the Roche Group, which enhances their capabilities and reach in the biotechnology market. Their recent investment in a Gene Therapy Innovation Center underscores their commitment to advancing gene therapy manufacturing and research, further solidifying their position in the biotechnology sector.

2. Seattle Genetics

• Website: seattlegenetics.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: seattle-genetics

Seattle Genetics, based in Bothell, Washington, is a biopharmaceutical company founded in 1998. The company is dedicated to developing and manufacturing innovative therapies for cancer treatment, particularly through its pioneering work in antibody-drug conjugates (ADCs). Seattle Genetics is known for its flagship product, Adcetris, which has been approved for the treatment of certain types of lymphoma. The company continues to expand its product pipeline, focusing on targeted therapies that aim to improve patient outcomes while reducing side effects. With a workforce of over 2,000 employees, Seattle Genetics is actively engaged in clinical trials and research initiatives to bring new therapies to market, demonstrating its commitment to advancing cancer treatment.

3. FUJIFILM Diosynth Biotechnologies

• Website: fujifilmdiosynth.com
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: Denmark 43%, United States (USA) 40%, United Kingdom (UK) 17%
• Latest funding: $890.0M, August 2019
• Founded year: 2011
• Headcount: 1001-5000
• LinkedIn: fujifilm-diosynth-biotechnologies

FUJIFILM Diosynth Biotechnologies is a biotechnology company based in Morrisville, North Carolina, specializing in contract development and manufacturing services for biologics, vaccines, and advanced therapies. Founded in 2011, the company has quickly established itself as a key player in the biotechnology sector. It partners with pharmaceutical and biotechnology firms to provide expertise in cGMP processes, ensuring that products are developed and manufactured to the highest safety and efficacy standards. With a workforce of over 5,000 employees distributed across facilities in the United States, Denmark, the United Kingdom, and Japan, FUJIFILM Diosynth Biotechnologies supports clients through all phases of drug development, from pre-clinical studies to commercialization. The company has made significant investments in expanding its capabilities, including a recent $890 million funding round aimed at enhancing its manufacturing capacity. This strategic focus on growth and innovation positions FUJIFILM Diosynth Biotechnologies as a relevant and active participant in the biotechnology industry.

4. Adimab

• Website: adimab.com
• Ownership type: Venture Capital
• Headquarters: Lebanon, New Hampshire, United States (USA)
• Employee distribution: United States (USA) 96%, Lebanon 4%
• Latest funding: January 2020
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: adimab-llc

Adimab, founded in 2007 and based in Lebanon, New Hampshire, is a biotechnology company focused on biologics discovery and engineering. The company specializes in developing therapeutic antibodies and multispecifics, leveraging a proprietary yeast-based platform that utilizes fully human synthetic diversity and immunized diversity. Over its 15 years of operation, Adimab has generated more than 500 therapeutic programs in collaboration with over 115 partners, including major pharmaceutical companies and biotech firms. With a strong emphasis on innovation, Adimab has contributed to over 70 clinical programs originating from its platform, showcasing its ability to translate target hypotheses into therapeutically relevant antibody drugs. The company has built a reputation for addressing challenges in drug development, making it a notable player in the biotechnology industry.

5. HemaCare Corporation, a Charles River Company

• Website: hemacare.com
• Ownership type: Corporate
• Headquarters: Los Angeles, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $380.0M, December 2019
• Founded year: 1978
• Headcount: 201-500
• LinkedIn: hemacare-corporation

HemaCare Corporation, a Charles River Company, is a biotechnology firm based in Los Angeles, California. Founded in 1978, the company specializes in providing a wide range of services related to cell sourcing and biologics testing. HemaCare is particularly known for its expertise in supplying human immune cells and stem cells, which are critical for advanced therapies and research in immunology and cell therapy. Their offerings include leukopaks, peripheral blood mononuclear cells (PBMCs), and hematopoietic stem and progenitor cells (HSPCs). HemaCare's services support pharmaceutical and biotechnology companies throughout the drug development continuum, from early research to clinical trials. The company is committed to ensuring compliance with regulatory standards, which is essential in the highly regulated biotechnology industry. HemaCare's integration into Charles River Laboratories enhances its capabilities, allowing it to provide comprehensive solutions that meet the evolving needs of its clients.

6. Sanyou Biopharmaceuticals Co., Ltd.

• Website: sanyoubio.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Latest funding: Series B, August 2022
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: sanyou-biopharmaceuticals-co-ltd

Sanyou Biopharmaceuticals Co., Ltd., founded in 2015 and based in Cambridge, Massachusetts, is a private equity-backed biopharmaceutical company. The firm specializes in the research and development of innovative biological drugs, offering a range of services that include integrated R&D platforms, antibody development, and protein production. Their clientele primarily consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. Sanyou operates on a global scale, with multiple locations in the United States and China, which enhances their ability to serve a wide array of clients. The company has not reported any recent funding, indicating a stable operational model that relies on its existing capabilities and market position.

7. Calico Life Sciences

• Website: calicolabs.com
• Ownership type: Venture Capital
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: Seed, January 2021
• Founded year: 2013
• Headcount: 201-500
• LinkedIn: calico-life-sciences-llc

Calico Life Sciences LLC, founded in 2013 and based in South San Francisco, California, is a biotechnology company dedicated to research and development in the field of aging and age-related diseases. The company aims to unravel the complexities of aging biology and translate that knowledge into innovative therapies. With a workforce of approximately 384 employees, Calico operates with a venture capital ownership model. Their research efforts are complemented by collaborations with academic institutions and pharmaceutical companies, notably AbbVie, which provides additional resources for drug discovery and development. Calico's clinical trials focus on conditions such as Vanishing White Matter Disease and Amyotrophic Lateral Sclerosis, showcasing their commitment to addressing significant health challenges associated with aging. The company emphasizes a culture of scientific inquiry and collaboration, positioning itself as a unique player in the biotechnology sector.

8. Atlas Venture

• Website: atlasventure.com
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2015
• Founded year: 1984
• Headcount: 11-50
• LinkedIn: atlas-venture

Atlas Venture is a private biotechnology investment firm based in Cambridge, Massachusetts, founded in 1984. The firm specializes in building breakthrough biotech companies by collaborating with life science entrepreneurs. Atlas Venture provides not only capital but also essential resources to help translate scientific advancements into commercial products. Over the years, they have launched more than 70 startups and have been involved in the development of over 25 medicines through their portfolio companies. Their investment strategy focuses on identifying transformative innovations in the biotech field, and they have a strong track record of successful exits, including IPOs and mergers and acquisitions. Atlas Venture's commitment to fostering a collaborative and patient-centric culture underscores their dedication to improving patient outcomes through innovative therapies.

9. Versant Ventures

• Website: versantventures.com
• Ownership type: Private
• Headquarters: San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 64%, Canada 19%, Switzerland 16%
• Founded year: 1999
• Headcount: 11-50
• LinkedIn: versant-ventures

Versant Ventures is a private venture capital firm based in San Francisco, California, founded in 1999. The firm specializes in biotechnology and has a strong focus on translating scientific discoveries into viable business ventures. With $4.2 billion in assets under management, Versant Ventures partners with academic institutions to create and fund innovative biotechnology companies. They operate through their Discovery Engines, which are in-house teams of scientists working in state-of-the-art laboratories. These teams are dedicated to launching novel biotech companies, leveraging academic research to drive innovation. Versant Ventures has a notable portfolio that includes companies like Black Diamond Therapeutics and Bright Peak Therapeutics, showcasing their active role in the biotechnology sector. Their commitment to advancing healthcare through biotechnology is evident in their extensive partnerships and successful company launches.

10. NPS Pharma

• Website: shire.com
• Ownership type: Corporate
• Headquarters: Bedminster, New Jersey, United States (USA)
• Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, Other 25%
• Latest funding: $86.4B, April 2018
• Founded year: 1986
• Headcount: 201-500
• LinkedIn: nps-pharmaceuticals

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, the company specializes in the research, development, manufacturing, and marketing of innovative medicines. NPS Pharma is particularly known for its work in therapeutic areas such as gastrointestinal diseases, rare diseases, oncology, and vaccines. The company aims to provide solutions for patients with limited or no treatment options, focusing on life-transforming therapies. NPS Pharma's involvement in the biotechnology industry is marked by its commitment to advancing medical science and improving patient outcomes through targeted research and development efforts. As part of Takeda, NPS Pharma benefits from a robust pipeline and global reach, enhancing its ability to impact healthcare positively.

11. Takara Bio USA, Inc.

• Website: takarabio.com
• Ownership type: Corporate
• Headquarters: San Jose, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $35.9M, March 2017
• Founded year: 1984
• Headcount: 201-500
• LinkedIn: takarabiousa

Takara Bio USA, Inc., based in San Jose, California, is a biotechnology company founded in 1984. The company specializes in providing a wide array of products and services, including kits, reagents, and instruments tailored for molecular biology research. Their offerings are crucial for researchers engaged in gene discovery, regulation, and function analysis. Takara Bio USA serves a clientele primarily composed of academic and clinical researchers, emphasizing their role in supporting scientific inquiry and innovation. The company is part of the Takara Bio Group, which holds a significant position in the global biotechnology market. Their mission focuses on enhancing human health through the development of high-quality, innovative tools and services that accelerate scientific discovery. Takara Bio USA is also involved in various applications, including next-generation sequencing, real-time PCR, and stem cell research, showcasing their commitment to advancing biotechnology.

12. BioLegend

• Website: biolegend.com
• Ownership type: Corporate
• Headquarters: San Diego, California, United States (USA)
• Employee distribution: United States (USA) 92%, Taiwan 3%, Other 5%
• Latest funding: $5.2B, July 2021
• Founded year: 2002
• Headcount: 501-1000
• LinkedIn: biolegend

BioLegend, founded in 2002 and headquartered in San Diego, California, is a biotechnology company that specializes in the development and manufacturing of antibodies and reagents tailored for biomedical research. The company serves a wide array of researchers in both academia and industry, providing essential tools that facilitate advancements in various scientific fields, including neuroscience, immunology, oncology, and proteogenomics. BioLegend is committed to delivering high-quality products and custom solutions, which are crucial for researchers aiming to achieve precise results in their studies. With a workforce of approximately 677 employees, the company operates globally, ensuring that their innovative products reach a broad audience. In July 2021, BioLegend secured significant funding, amounting to $5.25 billion, which underscores investor confidence in their business model and growth potential. This financial backing allows them to continue expanding their product offerings and enhancing their research capabilities.

13. Aldevron

• Website: aldevron.com
• Ownership type: Corporate
• Headquarters: Fargo, North Dakota, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $9.6B, June 2021
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: aldevron

Aldevron, based in Fargo, North Dakota, is a biotechnology company founded in 1998. The firm specializes in the manufacturing of high-quality plasmid DNA, RNA, proteins, and enzymes, which are essential for research and clinical applications. Aldevron serves a wide range of clients in the biotechnology and pharmaceutical sectors, providing crucial biological materials that support drug development and gene therapy initiatives. The company operates with a strong emphasis on quality and regulatory compliance, ensuring that their products meet the rigorous standards required in the life sciences industry. With over 1,000 clients relying on their products, Aldevron has become a trusted partner in advancing cell and gene therapies. Their recent funding of $9.6 billion in June 2021 highlights their significant role and ongoing relevance in the biotechnology landscape.

14. Nimbus Therapeutics

• Website: nimbustx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: nimbus-therapeutics

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to the discovery and development of small molecule therapeutics. The company specializes in tackling complex diseases, particularly in the areas of immunology, oncology, and metabolism. By utilizing advanced drug discovery techniques, Nimbus aims to create innovative treatment solutions that can significantly impact patient care. Their approach involves a collaborative structure-based drug discovery engine, which leverages cutting-edge technologies and expertise in computational chemistry and structural biology. This enables them to identify and drug targets that are often challenging for other companies. Recently, Nimbus secured $210 million in funding, underscoring their active role in the biotechnology sector and their potential for future growth.

15. Evozyne

• Website: evozyne.com
• Ownership type: Venture Capital
• Headquarters: Chicago, Illinois, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $81.0M, September 2023
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: evozyne

Evozyne is a biotechnology firm based in Chicago, Illinois, founded in 2020. The company specializes in the development of novel protein systems aimed at solving critical health challenges. Their focus is on creating high-performance therapeutic proteins and gene editing technologies, collaborating with pharmaceutical companies to enhance drug development processes. Evozyne employs generative AI and evolutionary principles to design adaptive proteins, which allows them to tackle complex therapeutic challenges. They are currently developing products such as IgG proteases, which modulate immune responses, and a portfolio of high-performance CRISPR gene editors. Evozyne has secured significant funding, with an $81 million Series B round completed in September 2023, reflecting strong investor interest in their innovative approach and potential for impactful solutions in healthcare.

16. Generate:Biomedicines

• Website: generatebiomedicines.com
• Ownership type: Venture Capital
• Headquarters: Somerville, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2024
• Founded year: 2018
• Headcount: 201-500
• LinkedIn: generate-biomedicines

Generate:Biomedicines, founded in 2018 and based in Somerville, Massachusetts, is a biotechnology company that specializes in the development of innovative protein therapeutics. The company operates at the intersection of machine learning and biological engineering, pioneering generative biology to create breakthrough medicines. Their proprietary platform, known as The Generate Platform, allows for the rapid generation of novel proteins tailored to specific therapeutic functions. This approach not only enhances the speed of drug discovery but also increases the success rates of developing effective treatments. Generate:Biomedicines has generated over 42,000 proteins and is actively working on a pipeline that includes therapies for severe asthma, atopic dermatitis, and various forms of cancer. Their recent collaboration with Novartis highlights their commitment to advancing protein therapeutics and underscores their role in the evolving biotechnology landscape.

17. Prilenia

• Website: prilenia.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, Israel 30%, Netherlands 12%, Other 16%
• Latest funding: Series B, $43.0M, November 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: prilenia

Prilenia Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, founded in 2018. The company is dedicated to developing novel therapeutics aimed at slowing the progression of neurodegenerative diseases, including Huntington's disease and amyotrophic lateral sclerosis (ALS). Prilenia is currently focused on its investigational drug, pridopidine, which is a selective sigma-1 receptor agonist. This drug is in late-stage clinical development and has been submitted for marketing approval in Europe for Huntington's disease. Prilenia has also received orphan drug designation for pridopidine in both the United States and the EU, highlighting its potential significance in treating these conditions. The company operates globally, with a workforce distributed across the United States, Israel, the Netherlands, Germany, and Spain. Prilenia's recent funding of $43 million in a Series B round in 2021 underscores its growth and the interest it has garnered from investors in the biotechnology sector.

18. Jounce Therapeutics, Inc.

• Website: jouncetx.com
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.9M, March 2023
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: jounce-therapeutics

Jounce Therapeutics, Inc. is a biotechnology firm based in Cambridge, Massachusetts, founded in 2013. The company focuses on pharmaceutical solutions and has recently made headlines with its acquisition of Theseus Pharmaceuticals, which underscores its commitment to enhancing drug development capabilities. Jounce Therapeutics primarily serves businesses in the biotechnology and pharmaceutical sectors, positioning itself as a player in the ongoing evolution of therapeutic innovations. With a workforce of approximately 51-200 employees, the company is relatively small but actively engaged in advancing its portfolio. In March 2023, Jounce secured $1.85 million in funding, reflecting ongoing investor interest in its potential.

19. Hexagon Bio

• Website: hexagonbio.com
• Ownership type: Venture Capital
• Headquarters: Menlo Park, California, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $77.3M, October 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: hexagon-bio

Hexagon Bio, founded in 2016 and based in Menlo Park, California, is a biotechnology firm dedicated to drug discovery and development, with a particular emphasis on cancer therapies. The company utilizes advanced techniques in genomics and synthetic biology to mine microbial genomes for novel medicines, including next-generation antibody drug conjugates. Their innovative platform combines computational biology and experimental methods to identify and produce compounds that target cancer-related proteins. Hexagon Bio has attracted significant investment, raising $77.3 million in a Series B funding round in October 2022, which underscores their potential in the industry. Their work aims to address critical gaps in cancer treatment, making them a relevant player in the biotechnology field.

20. Hemispherx Biopharma, Inc.

• Website: hemispherx.net
• Ownership type: Private
• Headquarters: Ocala, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.0M, February 2017
• Founded year: 1966
• Headcount: 11-50
• LinkedIn: hemispherx-biopharma-inc.

Hemispherx Biopharma, Inc., also known as AIM ImmunoTech, is a biotechnology firm based in Ocala, Florida. Founded in 1966, the company is dedicated to the research and development of immunology solutions aimed at treating various diseases, particularly cancer and viral infections. Its flagship product, Ampligen® (rintatolimod), is an immuno-modulator that has demonstrated broad-spectrum activity in preclinical and clinical studies. Currently, Ampligen® is being evaluated in multiple clinical trials, including those for pancreatic cancer and chronic fatigue syndrome. The company has also received approval in Argentina for the treatment of severe chronic fatigue syndrome. Hemispherx is committed to advancing therapeutic options for patients and healthcare providers, focusing on areas such as immuno-oncology and viral diseases. The company has engaged in funding activities, with a reported last funding amount of $1 million in 2017, indicating ongoing efforts to support its research initiatives.

Biotechnology Insights: Key Companies in the US

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!